Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus

Fecha
2014-01-01
Autores
Director de tesis/Asesor
Título de la revista
ISSN de la revista
Título del volumen
Publicador
Elsevier
Editor
Compartir
Documentos PDF
Resumen
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment. © 2014 Fabio Bonilla-Abadía et al.
Descripción
Palabras clave
Citación
ARK
ARXIV
Barcode
Bibcode
EAN13
DOI
http://dx.doi.org/10.1155/2014/731806
EISSN
GOVDOC
Handle
IGSN
ISBN
ISMN
ISSN
0896-8411
ISTC
ISSN-L
LSID
Local
Other
http://www.scopus.com/inward/record.url?eid=2-s2.0-84893658088&partnerID=tZOtx3y1